MAP Pharmaceuticals, Inc.

• About Us 
  • Message from the CEO
  • Management Team
  • Board of Directors
  • Partnering
  • Contact Us
• Product Pipeline 
  • Pediatric Asthma Therapy
  • Inhaled Migraine Therapy
  • Asthma/COPD Therapy
  • Inhaled Diabetes Therapy
• Investor Relations 
  • IR Home
  • Press Releases
  • Events and Presentations
  • Corporate Governance
  • Management
  • Board of Directors
  • Committee Composition
  • Annual Reports
  • SEC Filings
  • Stock Information
  • Analyst Coverage
  • Contact Us
• Science & Technology 
• Publications 
  • Asthma
  • Migraine
  • Aerosol Science & Technology

Navigating the Path to Better Medicine

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical development. Unit Dose Budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and commercialization history.